{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:00:42Z","timestamp":1759960842336},"reference-count":11,"publisher":"Informa Healthcare","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1517\/13543784.10.6.1173","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T19:34:08Z","timestamp":1115235248000},"page":"1173-1193","source":"Crossref","is-referenced-by-count":2,"title":["92nd Annual Meeting of the American Association for Cancer Research"],"prefix":"10.1517","volume":"10","author":[{"given":"Carolyn","family":"Buser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sepp-Lorenzino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.1.139-148.2000"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000145200"},{"key":"CIT0022","first-page":"2289","volume":"61","author":"COHEN-JONATHAN E","year":"2001","journal-title":"Cancer Res"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V96.6.2246","volume":"96","author":"FANG G","year":"2000","journal-title":"Blood"},{"key":"CIT0041","first-page":"139","volume":"295","author":"BUCHDUNGER E","year":"2000","journal-title":"I Pharmacol Exp. Ther."},{"key":"CIT0042","first-page":"1031","volume":"344","author":"DRUKER BJ","year":"2001","journal-title":"RESTA DJ et a].: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. j Med."},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(00)79001-4"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8978"},{"key":"CIT0097","first-page":"2926","volume":"60","author":"BRUNS CJ","year":"2000","journal-title":"Cancer Res."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.10.6.1173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T06:39:02Z","timestamp":1586241542000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.10.6.1173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":11,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,2,24]]},"published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1517\/13543784.10.6.1173"],"URL":"https:\/\/doi.org\/10.1517\/13543784.10.6.1173","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}